Disc Medicine, Inc. (NASDAQ:IRON) Director Sells $10,313.31 in Stock

Disc Medicine, Inc. (NASDAQ:IRON) Director William Richard White sold 201 shares of the business’s stock in a transaction on Tuesday, October 1st. The stock was sold at an average price of $51.31, for a total value of $10,313.31. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

William Richard White also recently made the following trade(s):

• On Thursday, August 1st, William Richard White sold 201 shares of Disc Medicine stock. The stock was sold at an average price of $43.44, for a total value of $8,731.44.

Disc Medicine Stock Down 2.1 %

NASDAQ:IRON traded down $1.05 during mid-day trading on Thursday, hitting $50.15. 124,093 shares of the company traded hands, compared to its average volume of 351,703. The stock’s fifty day moving average price is $47.46 and its 200-day moving average price is $42.30. Disc Medicine, Inc. has a one year low of $25.60 and a one year high of $77.60. The firm has a market cap of $1.24 billion, a price-to-earnings ratio of -14.94 and a beta of 0.59.

Disc Medicine (NASDAQ:IRON) last released its earnings results on Thursday, August 8th. The company reported ($1.03) EPS for the quarter, topping analysts’ consensus estimates of ($1.11) by $0.08. Equities analysts predict that Disc Medicine, Inc. will post -4.19 EPS for the current year.

Analyst Upgrades and Downgrades

IRON has been the subject of a number of research analyst reports. Wells Fargo & Company assumed coverage on shares of Disc Medicine in a research note on Thursday, August 22nd. They issued an “overweight” rating and a $75.00 price target for the company. HC Wainwright reaffirmed a “buy” rating and issued a $70.00 target price on shares of Disc Medicine in a research report on Monday, September 16th. Cantor Fitzgerald reissued an “overweight” rating and set a $85.00 price target on shares of Disc Medicine in a report on Friday, September 20th. BMO Capital Markets reiterated an “outperform” rating and set a $70.00 price objective (up previously from $50.00) on shares of Disc Medicine in a research report on Monday, June 17th. Finally, Wedbush reissued an “outperform” rating and issued a $57.00 target price on shares of Disc Medicine in a research report on Friday, August 9th. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat, Disc Medicine presently has a consensus rating of “Moderate Buy” and an average target price of $64.13.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. Amalgamated Bank raised its holdings in Disc Medicine by 76.9% during the second quarter. Amalgamated Bank now owns 568 shares of the company’s stock valued at $26,000 after acquiring an additional 247 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in Disc Medicine during the 2nd quarter valued at approximately $129,000. ProShare Advisors LLC purchased a new position in Disc Medicine in the 1st quarter worth approximately $211,000. SG Americas Securities LLC boosted its stake in Disc Medicine by 44.2% in the 2nd quarter. SG Americas Securities LLC now owns 4,071 shares of the company’s stock worth $183,000 after purchasing an additional 1,247 shares during the period. Finally, Bleakley Financial Group LLC grew its holdings in Disc Medicine by 23.0% during the 1st quarter. Bleakley Financial Group LLC now owns 4,572 shares of the company’s stock valued at $285,000 after buying an additional 856 shares in the last quarter. Hedge funds and other institutional investors own 83.70% of the company’s stock.

About Disc Medicine

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.